In a new collaborative study, SCALE researchers and partners from France and Italy uncover how BDM91531, a high-affinity inhibitor, targets the AcrAB–TolC efflux pump in bacteria such as E. coli and Klebsiella pneumoniae.
This link will take you to a page that’s not on LinkedIn
